argenx

Opinion · Devil's advocate

Fact-check-o-meter

argenx's sales figures are consistent within its own release, but its trial messaging rounds off the misses

Vyvgart sales and profit in the third-quarter release match the interim statements in the same release. The gaps are in how trial news is framed: the quarterly update skips the Sjögren's futility stop, calls the myositis effect consistent across a subtype that missed significance, and names a celiac primary endpoint that differs from the one on ClinicalTrials.gov.

1. Press release vs filing · weight medium

   Quarterly update leaves out the Sjögren's trial stop

   The company said: "The story of argenx is one of continued innovation, growth and impact" source

   The record says: Two weeks earlier, a 6-K exhibit announced that argenx "will discontinue the Phase 3 UNITY study of efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease" because the IDMC "concluded that the UNITY study is unable to meet its primary endpoint." The October 22 third-quarter release, which lists Vyvgart's programs indication by indication, does not mention Sjögren's or UNITY. source

   Our view: The stop was disclosed promptly in its own filing, so this is an omission from the summary, not a hidden event. Still, a reader of the quarterly update alone would not learn that one of Vyvgart's expansion studies ended in futility this month.

2. Science · weight medium

   Myositis effect called consistent across a subtype that missed

   The company said: "Reported positive Phase 3 ALKIVIA results with consistent and clinically meaningful treatment effects observed across immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM)" source

   The record says: The August 17 topline 6-K shows the primary endpoint was met in the combined population (p=0.0011) and in IMNM (p=0.0048), but "In DM, a similar clinically meaningful improvement of 14.5 points (p=0.1093) was observed (51.51 vs 36.96), though statistical significance was not reached in this smaller cohort." The third-quarter release says only that argenx plans "to conduct an additional registrational study in DM." source

   Our view: The point estimates are similar, so "consistent" is defensible as a description of effect size. But the plan for a new DM trial follows a subtype result that did not reach significance (p=0.1093), and the quarterly update does not say why the extra study is needed. The near-term filing is IMNM only.

3. Science · weight medium

   Celiac release and trial registry name different primary endpoints

   The company said: "The primary endpoint was change from baseline in the ratio of villus height-to-crypt depth (Vh:Cd) at day 78 versus placebo" source

   The record says: The ClinicalTrials.gov record for the same study (NCT06982963), last updated November 18, 2025, lists one primary outcome: "Change from baseline in the VCIEL" at 78 days, with estimated enrollment of 100 and status still recruiting. The release treats VCIEL as a supporting measure that was "consistent with the primary endpoint" and reports 126 patients enrolled. The release gives p-values but no effect sizes for any measure. source

   Our view: This may be a stale registry entry rather than a switched endpoint; we cannot tell from public records. Either way, the readout is a histology measure in a controlled gluten challenge, not a real-world efficacy endpoint, and the numbers behind "clinically relevant" have not been shown. Phase 3 design will say more.

4. Legal and disclosure record · weight low

   No material litigation disclosed

   The record says: The 2025 Form 20-F states: "During the previous 12 months, there have not been any legal, governmental or arbitration proceedings (including any such proceedings which are pending or threatened of which we are aware) which may have, or have had in the recent past, significant effects on argenx and/or the Group's financial position or profitability." Note 26 adds that the company "is currently not facing any outstanding claims or litigation that may have a significant adverse impact." No securities litigation or enforcement disclosed in the latest annual filing. source

   Our view: The record is clean. Patent and biosimilar challenges are listed only as general risk factors, not as pending cases.

This is opinion. We compare the company's own announcements with its filings and the scientific record, and link every source. It is not an allegation of wrongdoing and not investment or legal advice. Legal items list only matters disclosed in filings or by courts and regulators. Checked Oct 23, 2026. Companies can respond through our right of reply.